18 August 2020
Latham Advises Seres Therapeutics in Public Offerings of Common Stock
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Peter Handrinos Lead | Latham & Watkins LLP | Partner | capital markets | Not stated |
| Wesley Holmes Lead | Latham & Watkins LLP | Partner | capital markets | Not stated |
| Jennifer Yoon | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Martha Anderson | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Ben Haas | Latham & Watkins LLP | Partner | FDA regulatory matters | Not stated |
| Chad Jennings | Latham & Watkins LLP | Associate | FDA regulatory matters | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax matters | Not stated |
| Samuel Weiner | Latham & Watkins LLP | Partner | tax matters | Not stated |
| Joseph Curran | Latham & Watkins LLP | Associate | tax matters | Not stated |
| Jeremiah Cowen | Latham & Watkins LLP | Associate | tax matters | Not stated |
| Alan Tamarelli | Latham & Watkins LLP | Partner | intellectual property matters | Not stated |
| Jiqiang Lin | Latham & Watkins LLP | Associate | intellectual property matters | Not stated |
Stated terms
- Stated value
- USD 246m (US$245.7 million)
- What the figure measures
- Total transaction value
- Client
- Seres Therapeutics, Inc.
- Counterparties
- Société des Produits Nestlé S.A. (Investor)